Does Cyclazodone Improve Focus and Cognition?

Cyclazodone is discussed in nootropics circles as a stimulant for focus, motivation, and sustained mental work. Human evidence, however, is extremely limited.

Most of what can be said with confidence comes from one older animal study and indirect human research on pemoline, a related prescription stimulant.

What Is Cyclazodone, and Why Does Pemoline Matter?

Cyclazodone, also known as cyclopropylpemoline, is a stimulant structurally related to pemoline. It appeared in the scientific literature during the 1960s but never became an established prescription medication.[1,2]

Pemoline was different. It was a prescription central nervous system stimulant, sold in the United States under the brand name Cylert, and used to treat attention-deficit/hyperactivity disorder (ADHD).[11,12] Because pemoline was actually used clinically, researchers were able to study its effects on attention, learning, fatigue, and task performance in humans.[4-9]

That makes pemoline relevant when trying to interpret claims about Cyclazodone, but the two compounds are not interchangeable. Human findings with pemoline can provide context, not proof of what Cyclazodone does.

Cyclazodone should also be distinguished from N-methyl-cyclazodone. A 2026 toxicokinetic study found that N-methyl-cyclazodone can undergo N-demethylation to form Cyclazodone, with CYP2A6 playing a major role in that metabolic pathway.[3] The study examined metabolism rather than cognitive effects.

Cyclazodone is often described online as acting on dopamine and norepinephrine transporters, but direct studies establishing its binding or uptake-inhibition activity at DAT, NET, or SERT were not identified in the primary literature reviewed for this article.

What Does “Focus” Mean in This Context?

“Focus” can describe several different experiences. A person may feel more alert, more motivated, less tired, or more willing to continue a repetitive task without necessarily becoming better at learning new information, remembering it, or performing other cognitive tasks.

That distinction matters when evaluating Cyclazodone because subjective stimulation and measurable cognitive enhancement are not the same outcome.

Cyclazodone has not been tested adequately enough in humans to determine whether it reliably improves any of these areas.

Has Cyclazodone Been Tested for Focus or Cognition?

The most relevant direct experiment appears to be a 1967 study by Segal and colleagues examining pemoline and cyclopropylpemoline, another name for Cyclazodone.[1]

Male rats were tested on a continuous avoidance schedule. Cyclopropylpemoline increased behavioural responding in a pattern the authors compared with d-amphetamine.

The study demonstrates stimulant-like behavioural activity in animals, but continuous avoidance responding is not equivalent to testing human attention, working memory, learning, or executive function.

No controlled human Cyclazodone study identified in the published literature directly tested those outcomes.

Does Pemoline Improve Learning and Memory in Healthy People?

In a 1967 double-blind study, Smith tested magnesium pemoline in healthy adult men using verbal learning, motor learning, short-term visual and auditory memory, 24-hour retention, reaction time, and other measures of performance.[4]

Pemoline did not improve learning, memory, or overall performance. Where statistically significant differences between groups occurred, they favoured placebo rather than pemoline.[4]

The study should not be interpreted as evidence that pemoline universally impairs cognition.

Does Pemoline Help Maintain Performance During Fatigue?

In fatigued participants, Gelfand and colleagues found that 100 mg of magnesium pemoline helped maintain speed and accuracy during repetitive arithmetic, while the 25 mg and 50 mg conditions did not differ significantly from placebo.[5]

Herbert and colleagues reported similar findings in fatigued men, with pemoline helping preserve performance during prolonged arithmetic work.[6]

These studies tested performance under fatigue rather than baseline cognitive enhancement.

What Did Pemoline Do in People With ADHD?

Conners and Taylor found that pemoline and methylphenidate improved behavioural and task-performance measures in children with attention disorders, while achievement measures did not show corresponding improvement.[7]

Sallee, Stiller, and Perel later examined pemoline in 25 boys with attention-deficit disorder with hyperactivity.[8] Their assessments included memory-search efficiency and paired-associate learning, and they reported effects on information processing, including improvement in memory-search efficiency.

Pemoline was also evaluated in adults. In a 10-week double-blind, placebo-controlled crossover trial, Wilens and colleagues studied 35 adults with ADHD.[9] Half of the participants receiving pemoline met the study’s response criterion compared with 17% during placebo treatment.

These trials tested treatment effects in people with attention disorders.

Does Stimulant-Like Performance Mean Better Cognition?

Smith tested learning and memory in healthy adults and did not find enhancement.[4] Gelfand and Herbert measured whether fatigued participants could maintain repetitive arithmetic performance.[5,6] ADHD trials examined symptom control and task performance in clinical populations.[7-9]

Feeling more driven, remaining on a task for longer, maintaining performance while tired, and performing better on attention-related measures in ADHD are all different from improving learning, memory, or executive function in a healthy person.

A subjective sense of greater focus or productivity is therefore not, by itself, evidence of cognitive enhancement.

What Do We Know About Cyclazodone’s Safety?

There is no adequate human clinical dataset establishing Cyclazodone’s common adverse effects, long-term tolerability, cardiovascular effects, liver safety, or a medically validated therapeutic dose.

Cyclazodone cannot be assumed to share the toxicity profile of related compounds, but the absence of reported clinical toxicity is not evidence that it is safe.

Does Pemoline’s Liver Risk Apply to Cyclazodone?

Nehra and colleagues analysed reports of pemoline-associated hepatic injury and described a predominantly hepatocellular pattern of damage.[10]

Serious liver toxicity eventually changed pemoline’s regulatory status. Manufacturers stopped marketing Cylert in the United States in 2005 after the FDA concluded that the risk of pemoline-induced liver failure outweighed its benefits. The FDA formally withdrew the relevant approvals in 2023.[11]

Pemoline’s hepatotoxicity does not establish that Cyclazodone causes the same injury. Structural similarity alone is not sufficient to assume identical toxicity.

Cyclazodone has not undergone sufficient human safety testing to determine whether its liver risk is similar, lower, greater, or unrelated.

Bottom Line

Cyclazodone has demonstrated stimulant-like behavioural activity in animals, but its reputation as a cognitive enhancer goes beyond the available human evidence.

Human research on the related prescription stimulant pemoline shows that maintaining performance under fatigue, treating impaired attention, and improving learning or memory are different outcomes.

Cyclazodone is better described as an inadequately studied stimulant with claimed nootropic effects than as a demonstrated cognitive enhancer.

References

1. Segal, D. S., et al. (1967). Stimulatory effects of pemoline and cyclopropylpemoline on continuous avoidance behavior: Similarity to effects of D-amphetamine. Life Sciences. https://doi.org/10.1016/0024-3205(67)90322-0
2. Docherty, J. R. (2008). Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). British Journal of Pharmacology, 154(3), 606-622. https://doi.org/10.1038/bjp.2008.124
3. Gampfer, T. M., et al. (2026). Toxicokinetic studies of the two stimulants M-ALPHA and N-methyl-cyclazodone using in vitro and in vivo tools. Metabolites, 16(5), 291. https://doi.org/10.3390/metabo16050291
4. Smith, R. C. (1967). Magnesium pemoline: Lack of facilitation in human learning, memory, and performance tests. Science, 155(3762), 603-605. https://doi.org/10.1126/science.155.3762.603
5. Gelfand, S., et al. (1968). Magnesium pemoline: Stimulant effects on performance of fatigued subjects. Clinical Pharmacology & Therapeutics, 9(1), 56-60. https://doi.org/10.1002/cpt19689156
6. Herbert, M., et al. (1968). Magnesium pemoline: Stimulant effects on performance of fatigued men. Clinical Pharmacology & Therapeutics, 9(5), 578-581. https://doi.org/10.1002/cpt196895578
7. Conners, C. K., & Taylor, E. (1980). Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Archives of General Psychiatry, 37(8), 922-930. https://doi.org/10.1001/archpsyc.1980.01780210080009
8. Sallee, F. R., Stiller, R. L., & Perel, J. M. (1992). Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. Journal of the American Academy of Child & Adolescent Psychiatry, 31(2). https://doi.org/10.1097/00004583-199203000-00010
9. Wilens, T. E., et al. (1999). Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology, 19(3), 257-264. https://doi.org/10.1097/00004714-199906000-00009
10. Nehra, A., Mullick, F., Ishak, K. G., & Zimmerman, H. J. (1990). Pemoline-associated hepatic injury. Gastroenterology, 99(5), 1517-1519. https://doi.org/10.1016/0016-5085(90)91186-A
11. U.S. Food and Drug Administration. (2023). Determination that CYLERT (pemoline) tablets and chewable tablets were withdrawn from sale for reasons of safety or effectiveness. Federal Register, 88, 36989-36990.
12. Mayo Clinic. Pemoline (oral route): Description and clinical use. Mayo Clinic.